Nelson N. Stone, MD

Icahn School of Medicine at Mount Sinai

New York, New York

Nelson N. Stone, MD, is Professor of Urology, Radiation Oncology, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai and chief medical officer at Viomerse, Inc.

Dr. Stone earned his medical degree from the University of Maryland in 1979. He completed a Residency in General Surgery in 1981 at the University of Maryland, followed by a Residency in Urology at the University of Maryland. He then completed a Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center and a Research Fellowship in Biochemical Endocrinology at Rockefeller University in 1986. He was Chief of Urology at Elmhurst Hospital Queens from 1986-1996.

Dr. Stone has founded several medical companies and serves on the editorial board of many scientific journals. He is a member of many professional societies, including the Prostate Conditions Education Council, the Society for Minimally Invasive Therapy, the New York State Urological Society, the American Association of Clinical Urologists, and the American Urologic Association. Dr. Stone has participated in approximately 25 research studies on prostate cancer and has authored more than 500 articles, abstracts, and book chapters, primarily on prostate cancer. He invented the real-time technique for prostate brachytherapy in 1990 and has trained more than 5,000 physicians worldwide through his company ProSeed. His most recent company, Viomerse, creates synthetic body parts (phantoms) for surgical training and has recently released an extended reality remote training platform.

Talks by Nelson N. Stone, MD

Can One Biopsy Event Determine Type and Amount of Focal Therapy Treatment?

Posted by Nelson N. Stone, MD | May 2021

Nelson N. Stone, MD, Professor of Urology, Radiation Oncology, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai and at the Derald H. Ruttenberg Cancer Center at Mount Sinai argues for the use of Transperineal Mapping Biopsy (TPMB), and against the use of strict criteria and cursory cancer identification methods for finding Focal Therapy eligible patients. He expresses a clinical need for a process that identifies Focal Therapy candidates and lists which portions of the prostate require treatment. He suggests that TPMB can fulfill these goals. Dr. Stone summarizes a review of the evidence for using focal therapy for the treatment of prostate cancer and found that despite at least 50% of patients being Focal Therapy eligible only a minority of patients actually receive the therapy. He critiques a study on Focal Therapy eligibility determined by MRI/US fusion biopsy on the basis of using too strict of criteria for selecting patients and in consideration of the possibility of missing many patients due to not using a biopsy. Dr. Stone discusses several other studies that depict MRI as unreliable in accurately identifying Focal Therapy patients compared to TPMP due to the lower accuracy of MRI across the prostate.

Role of Brachytherapy in High-Risk Prostate Cancer

Posted by Nelson N. Stone, MD | Sep 2019

Nelson N. Stone, MD, explains that many studies show benefits from combination external beam radiation therapy (EBRT) and brachytherapy in high-risk prostate cancer patients. He then discusses potential reasons for these benefits and the impact of brachytherapy dosage in patient outcomes.

Advanced PET Imaging for Prostate Cancer Staging

Posted by Nelson N. Stone, MD | Aug 2019

Nelson N. Stone, MD, discusses the importance of precisely locating sites of failure in recurrent prostate cancer patients. He focuses on how new positron emission tomography (PET)/CT imaging agents can improve detection, noting the need for improved detection methods in patients with low PSA levels.

Transperineal Mapping Biopsy Defines Tumor Type and Location

Posted by Nelson N. Stone, MD | Jul 2019

Nelson N. Stone, MD, reviews the limitations of systematic biopsy and MRI in regard to accurately localizing and grading of prostate cancer tumors. He describes a 3D transperineal biopsy platform that could improve tumor localization and provide a pathway to targeted focal therapy.

Long-Term Erectile Dysfunction and Urinary Morbidity Following Brachytherapy

Posted by Nelson N. Stone, MD | Jun 2019

Nelson N. Stone, MD, identifies high-risk factors for erectile dysfunction and urinary morbidity and discusses management strategies for preventing these complications when treating patients with brachytherapy. He specifically addresses seed implementation techniques in patients with prior prostate surgery and large glands, as well as managing post-implantation symptoms.